ALMS

AI Memo

Alumis

As of 2026-09-10/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-10 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Psoriasis NDA filing checkpoint • 2026-12-31

Base target: $9 / p=45% prob

Biggest risk

The overall-population LUMUS failure materially weakens the SLE thesis and raises uncertainty around regulatory acceptance of the IFNGS-high subgroup. The stock has already repriced sharply, but further downside remains possible if psoriasis execution or the biomarker strategy disappoints.

Invalidation

Break below $5 or thesis failure.

What would change my mind?

The residual bull case is centered on envudeucitinib's psoriasis efficacy, the planned Q4 2026 NDA filing, and a potential biomarker-defined SLE development path. ONWARD3 reported 54% PASI 100 at 48 weeks [#SEC-8K-2026-08-13].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-10

Base target

p=45%

Bull target

$16

p=20%

Bear target

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

LUMUS overall-population failure resets sentiment
Biomarker-defined SLE development path
The residual bull case is centered on envudeucitinib's psoriasis efficacy, the planned Q4 2026 NDA filing, and a potential biomarker-defined SLE development path.

BearKey bullets

A planned psoriasis NDA filing is not approval; review, labeling, safety, and commercial execution risks remain [#SEC-8K-2026-08-13].
LUMUS failed its primary and secondary endpoints in the overall SLE population [#PR-EARNINGS-2026-09-01].
Recent director Form 4 activity includes open-market purchases and sales, but it is secondary context and does not establish operating improvement [#SEC-FORM4-2026-09-09].

WatchKey bullets

Psoriasis NDA filing checkpoint

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $9 (p=45%)

Target spread vs base: +88% / -47%

Scenario probabilities

Bull Target: $16 (p=20%)Base Target: $9 (p=45%)Bear Target: $5 (p=35%)

Commentary

News tone is strongly negative after the September 1 LUMUS readout and reported roughly 57%-58% selloff. The $9.80 anchor reflects substantial post-event repricing. The remaining positive evidence is concentrated in psoriasis efficacy, the Q4 2026 NDA plan, and the IFNGS-high SLE subgroup. Social, options, short-interest, employee-review, and analyst-revision coverage are unavailable or incomplete, so this remains a high-volatility monitoring setup rather than a high-conviction recovery call.

As of 2026-09-10 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

LUMUS overall-population failure resets sentiment
Biomarker-defined SLE development path

Scenarios

Bull Target (Scenario probability)

$16 / p=20% prob

Base Target (Scenario probability)

$9 / p=45% prob

Bear Target (Scenario probability)

$5 / p=35% prob

Analysis 2026-09-10 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.88

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Psoriasis NDA filing checkpoint
Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026; ONWARD3 showed 54% PASI 100 at 48 weeks [#SEC-8K-2026-08-13].
Prob 70.00% • Move 25.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

LUMUS overall-population failure resets sentiment
2026-09-01
The Phase 2b LUMUS trial missed its primary and secondary endpoints in the overall SLE population, although a prespecified IFNGS-high subgroup showed robust responses [#PR-EARNINGS-2026-09-01].
Prob 100% • Move -55% • Priced-in 100%

Long-term Catalysts

Months to a year

Biomarker-defined SLE development path
2027-09-10
The company plans regulatory engagement on Phase 3 development based on IFNGS-high subgroup results, but the regulatory outcome and timing remain uncertain [#PR-EARNINGS-2026-09-01].
Prob 35% • Move 30% • Priced-in 10%

Risks

A planned psoriasis NDA filing is not approval; review, labeling, safety, and commercial execution risks remain [#SEC-8K-2026-08-13].
LUMUS failed its primary and secondary endpoints in the overall SLE population [#PR-EARNINGS-2026-09-01].
Recent director Form 4 activity includes open-market purchases and sales, but it is secondary context and does not establish operating improvement [#SEC-FORM4-2026-09-09].
The IFNGS-high subgroup was under-represented, limiting confidence in broader SLE efficacy and leaving the Phase 3 regulatory path unresolved [#PR-EARNINGS-2026-09-01].
The post-readout repricing and incomplete analyst-revision data make near-term volatility and thesis dispersion high.

Peers

Symbol	Summary
ARQT	Dermatology-biotech peer with more commercial footing; useful for framing psoriasis launch expectations.
CLDX	Near-cap clinical biotech peer, but with limited direct read-across to Alumis's TYK2 and psoriasis programs.
IOVA	Near-cap biotech peer with a materially different development and commercial profile; valuation comparison is loose.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-10

Loading AI feed…

Symbol

Summary

ARQT

Dermatology-biotech peer with more commercial footing; useful for framing psoriasis launch expectations.

CLDX

Near-cap clinical biotech peer, but with limited direct read-across to Alumis's TYK2 and psoriasis programs.

IOVA

Near-cap biotech peer with a materially different development and commercial profile; valuation comparison is loose.